drugset / Trial / NCT02462837
Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement
Phase 2
Terminated
11 enrolled
Southern Illinois University
Astellas Scientific & Medical Affairs, Inc. · collabSisters of the Third Order of St. Francis · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.
Timeline
- Start
- 2015-05
- Primary completion
- 2019-01-30
- Completion
- 2019-01-30
Outcome
Outcome not reported
Stopped (Enrollment): “insufficient rate of accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | Oral |